Immedica's $151M Acquisition of Marinus Pharmaceuticals Boosts Rare Disease Portfolio and Revenue Growth

Immedica Pharma AB, a leading global rare disease company, has announced its intention to acquire Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) in a deal valued at approximately $151 million. The acquisition, which is expected to close in the first quarter of 2025, will strengthen Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a commercial-stage rare neurology medicine approved by the FDA, European Commission, UK MHRA, and China's NMPA. This strategic move is anticipated to drive Immedica's revenue growth and expand its presence in the North American market.



ZTALMY, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, is approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older. The acquisition of Marinus Pharmaceuticals will grant Immedica global rights to ZTALMY, with potential for further approvals worldwide. This addition to Immedica's portfolio is expected to accelerate its revenue growth by adding a commercial-stage asset in the United States, with the potential for further expansion globally.

Immedica will commence a cash tender offer to acquire all issued and outstanding shares of Marinus for USD 0.55 per share, corresponding to an implied enterprise value of approximately USD 151 million. The Board of Directors of Marinus has unanimously approved the transaction and recommended that stockholders tender their shares in the tender offer. Immedica has received an undertaking from each director and named executive officer of Marinus to tender their respective shares in favor of the transaction.

The acquisition of Marinus Pharmaceuticals represents a transformative step in Immedica's journey to further strengthen its position as a leading rare disease company. By adding ZTALMY to its portfolio, Immedica significantly strengthens its capabilities and expands its presence in the United States, marking a new chapter in its mission to deliver impactful therapies for underserved patient populations. The acquisition is expected to drive Immedica's revenue growth by adding a U.S.-based commercial asset with global expansion potential.



In conclusion, Immedica's acquisition of Marinus Pharmaceuticals is a strategic move that strengthens its global rare disease business, accelerates its revenue growth, and expands its presence in the North American market. The addition of ZTALMY to Immedica's portfolio is expected to drive significant value for both companies and their respective stockholders. As the transaction progresses, investors will closely monitor the integration and potential synergies between Immedica and Marinus Pharmaceuticals.